ReviewPharmacological reports : PR2025
Calycosin and kidney health: a molecular perspective on its protective mechanisms.
Review in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Trial
- Allicin inhibits kidney stone formation by suppressing the TNF/NF-κB pathway: Experimental validation through network pharmacology, in vitro, and in vivo studies.Molecular biology reports · 2026Article
- Bruceine A attenuates renal tubulointerstitial fibrosis by inhibiting the Wnt7a/PI3K/AKT pathway.Frontiers in pharmacology · 2026Article
- Regulatory networks of post-translational modifications in diabetic kidney disease: from pathogenic mechanisms to therapeutic frontiers.Frontiers in endocrinology · 2026Review
- Asiatic acid fromFrontiers in nutrition · 2026Article
- Retinol saturase promotes tubulointerstitial fibrosis in diabetic kidney disease by inhibiting ChREBP ubiquitination via Smurf2 suppression.Frontiers in endocrinology · 2026Article
- Elucidating the therapeutic efficacy and mechanisms of arctigenin in ameliorating renal fibrosis: a combined transcriptomic and proteomic study.Frontiers in pharmacology · 2026Article
- The Role of Sirt3 in Kidney Health and Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Traditional Chinese medicine in the prevention and treatment of lung cancer metastasis by regulating tumor-associated macrophages: a narrative review.Translational lung cancer research · 2025Review
- Protocatechualdehyde attenuates oxidative stress in diabetic cataract via GLO1-mediated inhibition of AGE/RAGE glycosylation.Frontiers in pharmacology · 2025Article
- Balanophora polysaccharide improves renal injury and fibrosis in db/db diabetic nephropathy mice via NLRP3 inflammasome mediated inflammation.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney diseases encompass a diverse group of pathological conditions characterized by the progressive loss of renal function, leading to systemic complications and increased morbidity. Their global prevalence increasing, posing a substantial public health challenge. The underlying pathophysiology involves complex molecular interactions that drive inflammation, fibrosis, and tissue injury. Notably, the AGE/RAGE axis activates NF-κB, a pivotal transcription factor responsible for pro-inflammatory cytokine production. This response is further intensified by NLRP3-inflammasome activation, which detects cellular stress and promotes IL-1β release. Additionally, TGF-β signaling through SMADs and MAPK pathways induces ECM accumulation, contributing to tissue fibrosis. Besides this, oxidative stress-induced ferroptosis and apoptosis also play critical roles in disease progression. Given the multifactorial nature of kidney diseases, agents with multi-targeted actions are promising for effective renoprotection. Significant research interest has emerged in exploring calycosin's protective effects against kidney-related pathologies, owing to its diverse pharmacological properties, including anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects. Calycosin is a naturally occurring isoflavone primarily found in Astragalus membranaceus, a well-known medicinal herb in traditional Chinese medicine. Several studies have demonstrated that calycosin exerts its renoprotective effects by modulating key molecular mediators, including RAGE, NF-κB, TGF-β, MAPKs, NLRP3-inflammasome, Nrf-2, PPARγ, and Sirtuin-3, among others, thereby providing a multitargeted defense against kidney diseases. Considering the potential of calycosin in modulating these mediators, the present study was conceptualized to study the mechanistic interplay underlying its renoprotective effects. By investigating these interconnected pathways, this study will provide foundational insights that will enable future researchers to address existing gaps and further elucidate calycosin's potential in renal disorders.
Indexed as
Identifiers
40249500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.